<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634501</url>
  </required_header>
  <id_info>
    <org_study_id>XuanWuH-NK</org_study_id>
    <nct_id>NCT03634501</nct_id>
  </id_info>
  <brief_title>Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells</brief_title>
  <official_title>Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will analyze and evaluate the following items:&#xD;
&#xD;
        1. The safety of natural killer（NK） cells for treatment of subjects with solid tumors.&#xD;
           Forty patients will be enrolled for each of the five cancers (in total 200 patients will&#xD;
           be enrolled).&#xD;
&#xD;
        2. The effectiveness of natural killer（NK）cell therapy alone or with chemotherapy or&#xD;
           targeted drugs.&#xD;
&#xD;
      Subjects from 18 to 75 years of age who are diagnosed with a solid tumor including pancreatic&#xD;
      cancer, lung cancer, breast cancer, ovarian cancer and colon cancer, and for whom standard&#xD;
      treatments are not effective, may be eligible for this study. Participants undergo the&#xD;
      following procedures:&#xD;
&#xD;
      Peripheral blood will be collected from a vein of arm. Peripheral blood mononuclear&#xD;
      cells（PBMC） will be isolated and purified for NK manufacturing. After 14~21 days cultivation,&#xD;
      activated NK will be harvested and formulated for clinical administration.&#xD;
&#xD;
      Subjects will receive NK cell treatment by intravenous infusion. The frequency is once every&#xD;
      3 or 4 weeks for the first 3 months. Participants who respond well after 3 months may be&#xD;
      eligible to continue NK cell therapy; and those not may receive NK therapy combined with&#xD;
      chemotherapy and/or targeted drugs, or chemotherapy/targeted drugs alone.&#xD;
&#xD;
      Evaluations during therapy including:&#xD;
&#xD;
        1. Clinical assessment, and history of medications;&#xD;
&#xD;
        2. Blood draws for routine and research tests, including but not limited to: lymphocyte&#xD;
           population and circulating tumor cell analysis in peripheral blood;&#xD;
&#xD;
        3. CT scan, bone scan and positron emission tomography（PET ）scan, if indicated, for disease&#xD;
           evaluation;&#xD;
&#xD;
        4. Pharmacokinetics study after NK infusion. For this test, the number of NK cells in the&#xD;
           blood is measured over time at indicated time-points.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of toxicity induced by NK infusion</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence of toxicity within each infusion within 6 months after NK administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective-response rate (ORR)</measure>
    <time_frame>6 months after 6 infusions of NK administration</time_frame>
    <description>Objective-response rate (ORR): defined as the proportion of patients who achieve partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at any time on study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of NK</measure>
    <time_frame>Day 0, Day 7, Day30, Day 60, Day 90, Day 180</time_frame>
    <description>Duration of NK persistence: defined as duration from Day 1 to the time when the NK level goes back to stable level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>NK cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Activated NK from peripheral blood and/or umbilical cord blood（UCB）</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Activated NK</intervention_name>
    <description>Cell suspension</description>
    <arm_group_label>NK cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18 to 75 years (including boundary values);&#xD;
&#xD;
          2. Diagnosed with histologically and cellularly confirmed cancer of lung, breast,&#xD;
             pancreas, ovary, or colon;&#xD;
&#xD;
          3. At least 8 weeks since any prior systemic therapy to treat the underlying malignancy&#xD;
             (standard or investigational);&#xD;
&#xD;
          4. Life expectancy &gt; 6 months, and performance status（KPS）&gt; 60 points;&#xD;
&#xD;
          5. Organ functions meet the following criteria:&#xD;
&#xD;
               1. Blood bilirubin &lt; 2mg/dL,&#xD;
&#xD;
               2. Aspartate transaminase（AST）&lt;100 IU/L,&#xD;
&#xD;
               3. Alanine transaminase（ALT） &lt;100 IU/L,&#xD;
&#xD;
               4. Creatinine &lt;1.5 mg/dL,&#xD;
&#xD;
               5. Urea nitrogen ≤ 25 mg/dL,&#xD;
&#xD;
               6. Hemoglobin ≥ 9.0 g/dL,&#xD;
&#xD;
               7. White blood cell count&gt;3.5×109/L,&#xD;
&#xD;
               8. Neutrophil count &gt;1.5x109/L,&#xD;
&#xD;
               9. Platelet count &gt; 80 × 109 /L,&#xD;
&#xD;
              10. Hematocrit &gt;0.20,&#xD;
&#xD;
          6. No severe infections.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who take combined systemic steroids within 2 weeks prior to treatment (except&#xD;
             inhaled steroids);&#xD;
&#xD;
          2. Patients who take chemotherapy within 1 month prior to treatment;&#xD;
&#xD;
          3. Subjects receiving drugs that stimulate the production of bone marrow hematopoietic&#xD;
             cells within two weeks prior to treatment;&#xD;
&#xD;
          4. Patients with T lymphoma and NK cell lymphoma;&#xD;
&#xD;
          5. Patients with autoimmune diseases, including but not limited to lupus erythematosus,&#xD;
             rheumatoid arthritis, etc.;&#xD;
&#xD;
          6. Seriously uncontrollable infected patients;&#xD;
&#xD;
          7. Patients who are allergic to the biological agents in this treatment;&#xD;
&#xD;
          8. Patients with organ transplantation or organ failure;&#xD;
&#xD;
          9. Subjects with severe cardiovascular disease and severe renal failure;&#xD;
&#xD;
         10. Patients who are undergoing treatment of immunosuppressive drugs or long-term&#xD;
             administration of immunosuppressive drugs after organ transplantation;&#xD;
&#xD;
         11. Patients with active infection or fever;&#xD;
&#xD;
         12. Subjects with severe cardiovascular and cerebrovascular diseases, diabetes and renal&#xD;
             dysfunction;&#xD;
&#xD;
         13. Subjects with pregnancy or during the lactating period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiguo Chen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiguo Chen, PhD</last_name>
    <phone>86-10-83198889</phone>
    <email>chenzhiguo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Zhao, PhD</last_name>
    <phone>86-10-83198274</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiguo Chen</last_name>
    </contact>
    <investigator>
      <last_name>Yu Zhao, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fei Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hua Kang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shijun Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Zhiguo Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

